Horizon Pharma gets favorable ruling in Ravicti patent infringement suit

Ireland-headquartered Horizon Pharma (Nasdaq: HZNP) has received a favorable Markman ruling issued by Judge Roy Payne in the US District Court for the Eastern District of Texas Marshall Division in the patent infringement lawsuit filed by Horizon against Par Pharmaceutical, for an Abbreviated New Drug Application to market a generic version of Ravicti (glycerol phenylbutyrate).

A Markman ruling, also known as a Claim Construction Ruling, is a determination by the court of the meaning and scope of disputed patent claim terms of certain patents in suit. Judge Payne was asked to construe disputed claim terms in US Patent Nos 8,404,215 and 8,642,012 and adopted Horizon's proposed construction of all but one of the disputed claim terms.

"We are pleased with the Court's ruling and are confident in the strength of the Ravicti patent estate," said Timothy Walbert, chairman, president and chief executive officer, Horizon Pharma.